<DOC>
	<DOCNO>NCT00313872</DOCNO>
	<brief_summary>To assess optimal sequence palliative chemotherapy regimen ( DP -- &gt; FOLFIRI v FOLFIRI -- &gt; DP ) metastatic gastric cancer patient .</brief_summary>
	<brief_title>Phase III Trial DP Followed FOLFIRI Reverse Sequence Unresectable Gastric Cancer</brief_title>
	<detailed_description>Gastric cancer second lead cause cancer death worldwide common malignancy Korea . Metastatic gastric cancer remain therapeutic challenge medical oncologist due poor prognosis . A recent phase III trial compare docetaxel-cisplatin-5-FU ( DCF ) reference arm cisplatin-5-FU ( CF ) show significant superiority DCF term survival , time-to-progression , response rate . However , DCF regimen associate high incidence toxicity , regimen yet widely accepted standard first-line chemotherapy gastric cancer patient . Thus , optimum front-line chemotherapy regimen extensively investigated patient improve survival .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>1 . Histologically confirm metastatic adenocarcinoma stomach 2 . Age â‰¥ 18 3 . Eastern Cooperative Oncology Group ( ECOG ) performance status less equal 2 4 . Life expectancy least 3 month 5 . Adequate renal , liver , bone marrow function 6 . Adjuvant chemotherapy 12 month date study entry 7 . Written inform consent 1 . Active infection require antibiotic 2 . Pregnant , lactate woman 3 . Brain metastasis 4 . Systemic illness appropriate chemotherapy 5 . Radiotherapy within 2 week study entry 6 . Allergy drug use trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>gastric cancer</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>irinotecan</keyword>
	<keyword>docetaxel</keyword>
</DOC>